Investor Relations

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris has initiated a Phase 2a proof of concept study of PRX302 for the treatment of localized low to intermediate risk prostate cancer during the 2nd quarter of 2015.

NASDAQ | SPHS $1.99 0.03 (1.485%)
High 2.08
Low 1.95
Volume 174,400
Market Cap 33.52M

11/25/15 10:56 AM ET

Pricing provided by eSignal
Delayed 20 minutes